The present disclosure, at least in part, relates to a miRNA based logic gate that comprises an engineered RNA carrier that comprises an nuclear export signal, a target site for a first miRNA and a pre-miRNA sequence for a second miRNA. Also provided by the disclosure are recombinant viruses (e.g., recombinant adeno-associated viruses (rAAV)) for delivery of the miRNA based logic gates.

The present disclosure, at least in part, relates to a miRNA based logic gate that comprises an engineered RNA carrier that comprises an nuclear export signal, a target site for a first miRNA and a pre-miRNA sequence for a second miRNA. Also provided by the disclosure are recombinant viruses (e.g., recombinant adeno-associated viruses (rAAV)) for delivery of the miRNA based logic gates.

The present invention provides a TNA-based probe for detecting and imaging a target miRNA in living cells. TNA-based probe is composed of a fluorophore-labeled TNA reporter strand partially hybridizing to a quencher-labeled TNA recognition strand which is designed to be antisense to the target RNA transcript via pair pairing. Upon cellular entry without the need of harmful transfection treatment, the quencher-labeled TNA recognition strand binds to targeted transcript, and these target binding events displace the reporter strand from the quencher, resulting in a discrete “turning-on” of the fluorescence. The extent of fluorescence enhancement is quantifiably related to the target RNA expression level. Additionally, the TNA-based probe shows rapid detection response, excellent selectivity and specificity toward target miRNAs and is able to distinguish the target molecules with 1-2 base mismatches.

The present invention provides a TNA-based probe for detecting and imaging a target miRNA in living cells. TNA-based probe is composed of a fluorophore-labeled TNA reporter strand partially hybridizing to a quencher-labeled TNA recognition strand which is designed to be antisense to the target RNA transcript via pair pairing. Upon cellular entry without the need of harmful transfection treatment, the quencher-labeled TNA recognition strand binds to targeted transcript, and these target binding events displace the reporter strand from the quencher, resulting in a discrete “turning-on” of the fluorescence. The extent of fluorescence enhancement is quantifiably related to the target RNA expression level. Additionally, the TNA-based probe shows rapid detection response, excellent selectivity and specificity toward target miRNAs and is able to distinguish the target molecules with 1-2 base mismatches.

The invention described herein provides reagents (e.g., kits), compositions, and methods for carrying out an unbiased genome-wide strategy to identify the functional targets for all ncRNAs.

The invention described herein provides reagents (e.g., kits), compositions, and methods for carrying out an unbiased genome-wide strategy to identify the functional targets for all ncRNAs.

The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.

The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.

Devices and kits for detecting molecular targets involved in the onset of parturition are presented, as are methods of using the same. The devices and kits include one or more associators specific for molecular targets, such as microRNAs and proteins and peptide fragments thereof. The associators, such as aptamers or antibodies, bind their targets, when such targets are present in a fluid sample from a pregnant woman, to produce a detectable signal. The signal may be produced in a lateral flow device.

The present invention provides, among other things, methods of detecting target nucleic acid, comprising steps of: a) contacting a sample with one or more capturing probes, each comprising at least one target capturing sequence, under conditions that permit the one or more capturing probes to capture one or more target nucleic acids in the sample; b) amplifying the captured one or more target nucleic acids in a reaction mixture comprising a detectable entity such that the amplified one or more target nucleic acids are labeled with the detectable entity; c) incubating amplification product with a plurality of re-capturing probes such that the amplified one or more target nucleic acids are re-captured by the plurality of the re-capturing probes; and d) detecting signal generated by detectable entity associated with the re-captured amplified one or more target nucleic acids, wherein the presence and/or abundance of the detectable signal indicates the presence and/or abundance of the one or more target nucleic acids in the sample.